Company intelligence / Profile preview

Yingu Pharmaceutical Co., Ltd.

Ownership: Private
Development stage: Other

Overview

Yingu Pharmaceutical has several products in various stages of development. Their lead product linperlisib (PI3Kδ inhibitor) showed 79.5% overall response rate in relapsed or refractory Follicular Lymphoma. Bencycloquidium bromide (BCQB), a novel M1/M3 receptor antagonist, is registered in China for allergic rhinitis. The company also has products like Salmon Calcitonin Nasal Spray which accounts for approximately 70% of the company's total revenue[4].

Therapeutic areas: OncologyPulmonologyRheumatologyImmunology
Modalities: Small moleculesBiologics
Industry: Biotech

Drug pipeline

1 asset

benquikium bromide

Partnerships

Jiangsu Hengrui MedicineMD Anderson Cancer Center

Beyond the preview

Go deeper on Yingu Pharmaceutical Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Yingu Pharmaceutical Co., Ltd..